Dermatologic adverse effects of breast cancer chemotherapy: a longitudinal prospective observational study with a review of literature
- 13 May 2020
- journal article
- review article
- Published by Wiley in International Journal of Dermatology
- Vol. 59 (7) , 822-828
Abstract
Background Breast cancer patients may experience an increased chance of survival with adjuvant chemotherapy. However dermatologic adverse effects can cause major discomfort due to physical or cosmetic problems. This study aims to describe dermatologic complications in breast cancer patients during chemotherapy. Methods This longitudinal prospective observational study included data on women with non‐metastatic breast cancer whom were treated with AC‐T protocol (anthracycline, cyclophosphamide, and taxane) adjuvant chemotherapy and consecutively enrolled during two years. The study was performed in an educational and tertiary referral center. The patients’ information including age, body mass index (BMI), past medical history, and different dermatologic complications were collected for all participants. Results Of 190 enrolled women, all patients experienced alopecia, which occurred in 131 patients (68.9%) after the first cycle. Skin, mucosal, and nail involvement were respectively seen in 46 (24.2%), 51 (26.8%), and 86 (45.2%) cases. Cutaneous complications were observed mainly between the third and sixth chemotherapy cycles. Palmoplantar erythema and palmoplantar dysesthesia were the most common cutaneous complications. Dermatologic adverse effects were significantly more frequent in the patients with an underlying disease. Conclusion These findings suggest that dermatologic adverse effects of adjuvant chemotherapy are common and could be induced by all components of AC‐T regimen. These complications should be skillfully managed to increase patients’ comfort.Keywords
This publication has 37 references indexed in Scilit:
- Chemotherapy and skin reactionsJournal of Experimental & Clinical Cancer Research, 2012
- Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trialThe Lancet, 2009
- Nail Toxicity Induced by Cancer ChemotherapyJournal of Oncology Pharmacy Practice, 2009
- Docetaxel-induced photolichenoid eruptionIndian Journal of Pharmacology, 2009
- Pegylated Liposomal Doxorubicin (Caelyx®) in Metastatic Breast Cancer: A Community-Based Observation StudyOncology, 2007
- Nail Toxicity after Treatment with Docetaxel: A Prospective Analysis in Patients with Advanced Non-small Cell Lung CancerJapanese Journal of Clinical Oncology, 2007
- Nail changes due to docetaxel—a neglected side effect and nuisance for the patientSupportive Care in Cancer, 2007
- Body mass index and cancer: Results from the Northern Sweden Health and Disease CohortInternational Journal of Cancer, 2005
- Persistent serpentine supravenous hyperpigmented eruption associated with docetaxelJournal of the European Academy of Dermatology and Venereology, 2005
- Nail Toxicity Related to Weekly Taxanes: An Important Issue Requiring a Change in Common Toxicity Criteria Grading?Journal of Clinical Oncology, 2002